bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure 3 from Identification of a Subset of Human Non–Small Cell Lung Cancer Patients with High PI3Kβ and Low PTEN Expression, More Prevalent in Squamous Cell Carcinoma
Authors: Cumberbatch Marie , Tang Ximing , Beran Garry , Eckersley Sonia , Wang Xin , Ellston Rebecca P.A. , Dearden Simon , Cosulich Sabina , Smith Paul D. , Behrens Carmen , Kim Edward S. , Su Xinying , Fan Shuqiong , Gray Neil , Blowers David P. , Wistuba Ignacio I. , Womack Chris
Published: April 2023

PDF file - 133K,Reduced nuclear PTEN in SCC compared with AC (TMA Set 1).
Supplementary Figure 1 from Identification of a Subset of Human Non–Small Cell Lung Cancer Patients with High PI3Kβ and Low PTEN Expression, More Prevalent in Squamous Cell Carcinoma
Authors: Cumberbatch Marie , Tang Ximing , Beran Garry , Eckersley Sonia , Wang Xin , Ellston Rebecca P.A. , Dearden Simon , Cosulich Sabina , Smith Paul D. , Behrens Carmen , Kim Edward S. , Su Xinying , Fan Shuqiong , Gray Neil , Blowers David P. , Wistuba Ignacio I. , Womack Chris
Published: April 2023

PDF file - 145K, Isoform specificity of PI3Kbeta antibody (AGG4888).
Supplementary Tables from Phase I Trial of a New Schedule of Romidepsin in Patients with Advanced Cancers
Authors: Amiri-Kordestani Laleh , Luchenko Victoria , Peer Cody J. , Ghafourian Kambiz , Reynolds James , Draper Deb , Frye Robin , Woo Sue , Venzon David , Wright John , Skarulis Monica , Figg William D. , Fojo Tito , Bates Susan E. , Piekarz Richard L.
Published: April 2023

Supplementary Tables - PDF file 33K, Supplementary Table 1. Dose levels, dose administered on each treatment day, days 1,3, and 5 of a 21-day cycle, and number of patients treated on each dose level. Supplementary Table 2. Romidepsin toxicities found in 9 patients enrolled at 9 mg/m2 during cycle 1 or in all cycles following treatment at 9 mg/m2. Supplementary Table 3. Cycle 1, Day 1 Romidepsin pharmacokinetic parameters (Mean plus-minus SD). Supplementary Table 4. ECG ST and T wave changes as pharmacodynamic marker
Supplementary Table 3 from Antagonism of SET Using OP449 Enhances the Efficacy of Tyrosine Kinase Inhibitors and Overcomes Drug Resistance in Myeloid Leukemia
Authors: Agarwal Anupriya , MacKenzie Ryan J. , Pippa Raffaella , Eide Christopher A. , Oddo Jessica , Tyner Jeffrey W. , Sears Rosalie , Vitek Michael P. , Odero María D. , Christensen Dale J. , Druker Brian J.
Published: April 2023

PDF file - 58KB, Combination index (CI) values.
Supplementary Figure 1 from Antagonism of SET Using OP449 Enhances the Efficacy of Tyrosine Kinase Inhibitors and Overcomes Drug Resistance in Myeloid Leukemia
Authors: Agarwal Anupriya , MacKenzie Ryan J. , Pippa Raffaella , Eide Christopher A. , Oddo Jessica , Tyner Jeffrey W. , Sears Rosalie , Vitek Michael P. , Odero María D. , Christensen Dale J. , Druker Brian J.
Published: April 2023

PDF file - 66KB, OP449 in combination with ABL1 tyrosine kinase inhibitors inhibits BCR-ABL1 signaling in CML cells and cellular growth of primary CML blastic phase cells ex vivo.
Supplementary Figure 2 from Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Dalantercept, an Activin Receptor–like Kinase-1 Ligand Trap, in Patients with Advanced Cancer
Authors: Bendell Johanna C. , Gordon Michael S. , Hurwitz Herbert I. , Jones Suzanne F. , Mendelson David S. , Blobe Gerard C. , Agarwal Neeraj , Condon Carolyn H. , Wilson Dawn , Pearsall Amelia E. , Yang Yijun , McClure Ty , Attie Kenneth M. , Sherman Matthew L. , Sharma Sunil
Published: April 2023

PDF file - 43K, Tumor blood flow response to dalantercept as assessed by DCE-MRI. Best response measured as maximum percent change from baseline in median Ktrans at day 15.
Supplementary Figure 4 from The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas
Authors: Gini Beatrice , Zanca Ciro , Guo Deliang , Matsutani Tomoo , Masui Kenta , Ikegami Shiro , Yang Huijun , Nathanson David , Villa Genaro R. , Shackelford David , Zhu Shaojun , Tanaka Kazuhiro , Babic Ivan , Akhavan David , Lin Kelly , Assuncao Alvaro , Gu Yuchao , Bonetti Bruno , Mortensen Deborah S. , Xu Shuichan , Raymon Heather K. , Cavenee Webster K. , Furnari Frank B. , James C. David , Kroemer Guido , Heath James R. , Hege Kristen , Chopra Rajesh , Cloughesy Timothy F. , Mischel Paul S.
Published: April 2023

PDF file - 1694K, EGFRvIII expression sensitizes cells to CC214-1 mediated inhibition of proliferation and to autophagy.
Supplementary Figure 1 from The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas
Authors: Gini Beatrice , Zanca Ciro , Guo Deliang , Matsutani Tomoo , Masui Kenta , Ikegami Shiro , Yang Huijun , Nathanson David , Villa Genaro R. , Shackelford David , Zhu Shaojun , Tanaka Kazuhiro , Babic Ivan , Akhavan David , Lin Kelly , Assuncao Alvaro , Gu Yuchao , Bonetti Bruno , Mortensen Deborah S. , Xu Shuichan , Raymon Heather K. , Cavenee Webster K. , Furnari Frank B. , James C. David , Kroemer Guido , Heath James R. , Hege Kristen , Chopra Rajesh , Cloughesy Timothy F. , Mischel Paul S.
Published: April 2023

PDF file - 3457K, Time course dependent CC214-1 treatment in a panel of isogenic GBM cell lines, U87EGFRvIII, U251 and LN229.
Supplementary Table 4 from Identification of microRNA-135b in Stool as a Potential Noninvasive Biomarker for Colorectal Cancer and Adenoma
Authors: Wu Chung Wah , Ng Siew Chien , Dong Yujuan , Tian Linwei , Ng Simon Siu Man , Leung Wing Wa , Law Wai Tak , Yau Tung On , Chan Francis Ka Leung , Sung Joseph Jao Yiu , Yu Jun
Published: April 2023

PDF file - 16KB, Sensitivity and specificity of miRNA markers.
Supplementary Table 3 from Identification of microRNA-135b in Stool as a Potential Noninvasive Biomarker for Colorectal Cancer and Adenoma
Authors: Wu Chung Wah , Ng Siew Chien , Dong Yujuan , Tian Linwei , Ng Simon Siu Man , Leung Wing Wa , Law Wai Tak , Yau Tung On , Chan Francis Ka Leung , Sung Joseph Jao Yiu , Yu Jun
Published: April 2023

XLSX file - 585KB, miRNA microarray data from 5 pairs of CRCs and 2 pairs of adenomas.
Supplementary Methods, Tables 1 - 2 from Neoadjuvant Imatinib in Advanced Primary or Locally Recurrent Dermatofibrosarcoma Protuberans: A Multicenter Phase II DeCOG Trial with Long-term Follow-up
Authors: Ugurel Selma , Mentzel Thomas , Utikal Jochen , Helmbold Peter , Mohr Peter , Pföhler Claudia , Schiller Meinhard , Hauschild Axel , Hein Rüdiger , Kämpgen Eckhardt , Kellner Ivonne , Leverkus Martin , Becker Jürgen C. , Ströbel Philip , Schadendorf Dirk
Published: April 2023

PDF file - 98K, Table 1. Toxicity of the intention to treat (ITT) population, classified and graded according to CTC 2.0 (http://ctep.cancer.gov/reporting/ctc.html). Data represent the worst CTC grade experienced by each patient. Table 2. Morphological and molecular tumor characteristics as analyzed in the per protocol (PP) population, for details see Patients and Methods. PDGFRB, platelet-derived growth factor receptor beta; EGFR, epidermal growth factor receptor; IR, insulin receptor; NA, not applicable.
Supplementary Table 1 from Characteristics and Clinical Impacts of the Immune Environments in Colorectal and Renal Cell Carcinoma Lung Metastases: Influence of Tumor Origin
Authors: Remark Romain , Alifano Marco , Cremer Isabelle , Lupo Audrey , Dieu-Nosjean Marie-Caroline , Riquet Marc , Crozet Lucile , Ouakrim Hanane , Goc Jeremy , Cazes Aurélie , Fléjou Jean-François , Gibault Laure , Verkarre Virginie , Régnard Jean-François , Pagès Olivier-Nicolas , Oudard Stéphane , Mlecnik Bernhard , Sautès-Fridman Catherine , Fridman Wolf-Herman , Damotte Diane
Published: April 2023

PDF file - 90K, Baseline characteristics of 140 patients with CRC lung metastasis. The stage was determined by pathological examination at the time of diagnosis.
Supplementary Figure Legend from Characteristics and Clinical Impacts of the Immune Environments in Colorectal and Renal Cell Carcinoma Lung Metastases: Influence of Tumor Origin
Authors: Remark Romain , Alifano Marco , Cremer Isabelle , Lupo Audrey , Dieu-Nosjean Marie-Caroline , Riquet Marc , Crozet Lucile , Ouakrim Hanane , Goc Jeremy , Cazes Aurélie , Fléjou Jean-François , Gibault Laure , Verkarre Virginie , Régnard Jean-François , Pagès Olivier-Nicolas , Oudard Stéphane , Mlecnik Bernhard , Sautès-Fridman Catherine , Fridman Wolf-Herman , Damotte Diane
Published: April 2023

PDF file - 81K
Supplementary Table 3 from Busulfan in Infant to Adult Hematopoietic Cell Transplant Recipients: A Population Pharmacokinetic Model for Initial and Bayesian Dose Personalization
Authors: McCune Jeannine S. , Bemer Meagan J. , Barrett Jeffrey S. , Scott Baker K. , Gamis Alan S. , Holford Nicholas H.G.
Published: April 2023

PDF file 34K, Acknowledgement of the institutions who used the FHCRC (1999-2001) or the SCCA Busulfan Pharmacokinetics Laboratory (2002-2011)
Supplementary Figure 3 from Altered Microenvironment Promotes Progression of Preinvasive Breast Cancer: Myoepithelial Expression of αvβ6 Integrin in DCIS Identifies High-risk Patients and Predicts Recurrence
Authors: Allen Michael D. , Thomas Gareth J. , Clark Sarah , Dawoud Marwa M. , Vallath Sabarinath , Payne Sarah J. , Gomm Jennifer J. , Dreger Sally A. , Dickinson Sarah , Edwards Dylan R. , Pennington Caroline J. , Sestak Ivana , Cuzick Jack , Marshall John F. , Hart Ian R. , Jones J. Louise
Published: April 2023

PDF file - 134K, Supplementary Figure 3. Organotypic of MDA-MB-231 + beta6-1089 staining.
Supplementary Figure 4 from Cabozantinib Inhibits Prostate Cancer Growth and Prevents Tumor-Induced Bone Lesions
Authors: Dai Jinlu , Zhang Honglai , Karatsinides Andreas , Keller Jill M. , Kozloff Kenneth M. , Aftab Dana T. , Schimmoller Frauke , Keller Evan T.
Published: April 2023

PDF file 114K, Impact of cabozantinib on angiogenesis and CD45+ myeloid cell infiltration of intratibial and soft tissue tumors in mice
CCR Translation for This Article from Cabozantinib Inhibits Prostate Cancer Growth and Prevents Tumor-Induced Bone Lesions
Authors: Dai Jinlu , Zhang Honglai , Karatsinides Andreas , Keller Jill M. , Kozloff Kenneth M. , Aftab Dana T. , Schimmoller Frauke , Keller Evan T.
Published: April 2023

CCR Translation for This Article from Cabozantinib Inhibits Prostate Cancer Growth and Prevents Tumor-Induced Bone Lesions
Supplementary Figure 2 from Antitumoral Activity of Lenalidomide in In Vitro and In Vivo Models of Mantle Cell Lymphoma Involves the Destabilization of Cyclin D1/p27KIP1 Complexes
Authors: Moros Alexandra , Bustany Sophie , Cahu Julie , Saborit-Villarroya Ifigènia , Martínez Antonio , Colomer Dolors , Sola Brigitte , Roué Gaël
Published: April 2023

PDF file - 6167K, (A) Flow cytometry analysis of cyclin D1 and p27KIP1 intracellular levels in a set of primary MCL samples (n=10, Table 1). In gray, isotypic control curves; in black, cyclin D1 and p27KIP1 curves. r indicates x-mean cyclin D1 or p27KIP1-Alexa-Fluor 647/xmean control ratio. (B) Semi-log curves time/f(p27KIP1 or cyclin D1/β-actin or β-tubulin) ratio deduced from densitometric analysis of cyclin D1 and p27KIP1 protein levels by Western blot in 4 MCL cell lines. (C) Time-dependent variation in cyclin D1 and p27KIP1 protein levels by SDS-PAGE in Ramos cells exposed for 3, 6 and 24 h to TAT-cyclin D1 fusion protein. β-tubulin was used as loading control.
Supplementary Tables 1 - 3 from DNA Methyltransferase Inhibition Reverses Epigenetically Embedded Phenotypes in Lung Cancer Preferentially Affecting Polycomb Target Genes
Authors: Hascher Antje , Haase Ann-Kristin , Hebestreit Katja , Rohde Christian , Klein Hans-Ulrich , Rius Maria , Jungen Dominik , Witten Anika , Stoll Monika , Schulze Isabell , Ogawa Seishi , Wiewrodt Rainer , Tickenbrock Lara , Berdel Wolfgang E. , Dugas Martin , Thoennissen Nils H. , Müller-Tidow Carsten
Published: April 2023

PDF file - 96K, Supplementary Table 1: Mutations detected in parental and highly metastatic NSCLC cell lines A549 (A) and HTB56 (B) by SNP analysis Supplementary Table 2: Mutations detected in parental and highly metastatic NSCLC cell lines A549 and HTB56 by Exome sequencing Supplementary Table 3: Conversion rate uniquely mapped reads
Supplementary Figures 4 - 6 from DNA Methyltransferase Inhibition Reverses Epigenetically Embedded Phenotypes in Lung Cancer Preferentially Affecting Polycomb Target Genes
Authors: Hascher Antje , Haase Ann-Kristin , Hebestreit Katja , Rohde Christian , Klein Hans-Ulrich , Rius Maria , Jungen Dominik , Witten Anika , Stoll Monika , Schulze Isabell , Ogawa Seishi , Wiewrodt Rainer , Tickenbrock Lara , Berdel Wolfgang E. , Dugas Martin , Thoennissen Nils H. , Müller-Tidow Carsten
Published: April 2023

PDF file - 1572K, Figure S4 4A+B): Column charts depict hypo- and hypermethylated regions detected by RRBS in high metastatic A549 (A) and HTB56 (B) cells after 6 days of 5-Azacytidine-treatment and after 7 days of 5-Azacytidine-release. 4C+D) Smoothed scatter plot of 5-Azacytidine-treated (250nM) versus untreated high metastatic HTB56 cells. Shown are methylation levels for CpG-sites analyzed by RRBS. C: X-axis: Methylation levels in HTB56 high metastatic cells (d0=untreated) Y-axis: Methylation levels in HTB56 high metastatic cells (d6_250= after six days of 5-Azacytidinetreatment, 5-Azacytidine-concentration of 250 nM) D: X-axis: Methylation levels in HTB56 high metastatic cells (d0=untreated) Y-axis: Methylation levels in HTB56 high metastatic cells (d13_250= after thirteen days of 5- Azacytidine-treatment, 5-Azacytidine-concentration of 250 nM) Figure S5 Unsupervised hierarchical clustering shows that 5-Azacytidine exposed cells cluster more closely together than individual cell lines. Figure S6 Chromosomal distribution of clusters and DMRs. The curves show the density distribution of hypomethylated DMRs and CpG clusters in relation to their chromosomal position: 0 indicates chromosomal end and 1 the centromeric region. Hypomethylated DMRs (green), hypermethylated DMRs (red) and CpG clusters (black) are shown. DNA demethylation upon 5-Azacytidine occurs primarily on chromosome ends.
Supplementary Figure 2 from DNA Methyltransferase Inhibition Reverses Epigenetically Embedded Phenotypes in Lung Cancer Preferentially Affecting Polycomb Target Genes
Authors: Hascher Antje , Haase Ann-Kristin , Hebestreit Katja , Rohde Christian , Klein Hans-Ulrich , Rius Maria , Jungen Dominik , Witten Anika , Stoll Monika , Schulze Isabell , Ogawa Seishi , Wiewrodt Rainer , Tickenbrock Lara , Berdel Wolfgang E. , Dugas Martin , Thoennissen Nils H. , Müller-Tidow Carsten
Published: April 2023

PDF file - 219K, Supplementary Figure 2 Chart depicts viability of high and low metastatic cells before 5-Azacytidine-treatment and after 7 days of 5-Azacytidine-release.
Supplementary Figure 1 from DNA Methyltransferase Inhibition Reverses Epigenetically Embedded Phenotypes in Lung Cancer Preferentially Affecting Polycomb Target Genes
Authors: Hascher Antje , Haase Ann-Kristin , Hebestreit Katja , Rohde Christian , Klein Hans-Ulrich , Rius Maria , Jungen Dominik , Witten Anika , Stoll Monika , Schulze Isabell , Ogawa Seishi , Wiewrodt Rainer , Tickenbrock Lara , Berdel Wolfgang E. , Dugas Martin , Thoennissen Nils H. , Müller-Tidow Carsten
Published: April 2023

PDF file - 233K, Supplementary Figure 1 Genomic changes in low and high metastatic A549 cells were analyzed by 500K SNP arrays.
Supplementary Figure 2 from MET Is a Potential Target across All Papillary Renal Cell Carcinomas: Result from a Large Molecular Study of pRCC with CGH Array and Matching Gene Expression Array
Authors: Albiges Laurence , Guegan Justine , Le Formal Audrey , Verkarre Virginie , Rioux-Leclercq Nathalie , Sibony Mathilde , Bernhard Jean-Christophe , Camparo Philippe , Merabet Zahira , Molinie Vincent , Allory Yves , Orear Cedric , Couvé Sophie , Gad Sophie , Patard Jean-Jacques , Escudier Bernard
Published: April 2023

PDF file - 50KB, Correlation between copy number alteration (blue - gain/amplification, red - loss) and gene expression profiling. Gene expression level is represented (in grey box plot), according to copy number alteration (each blue circle representing a CGH array results, diameter of circle depicts amplitude of gain).
Supplementary Figure Legends from MicroRNA-31 Predicts the Presence of Lymph Node Metastases and Survival in Patients with Lung Adenocarcinoma
Authors: Meng Wei , Ye Zhenqing , Cui Ri , Perry James , Dedousi-Huebner Vaia , Huebner Alexander , Wang Yao , Li Bin , Volinia Stefano , Nakanishi Hiroshi , Kim Taewan , Suh Sung-Suk , Ayers Leona W. , Ross Patrick , Croce Carlo M. , Chakravarti Arnab , Jin Victor X. , Lautenschlaeger Tim
Published: April 2023

PDF file, 64K.
Supplementary Table 2 from Glioma Grade Is Associated with the Accumulation and Activity of Cells Bearing M2 Monocyte Markers
Authors: Prosniak Michael , Harshyne Larry A. , Andrews David W. , Kenyon Lawrence C. , Bedelbaeva Kamila , Apanasovich Tatiyana V. , Heber-Katz Ellen , Curtis Mark T. , Cotzia Paolo , Hooper D. Craig
Published: April 2023

PDF - 69K, Gene-specific primers and probes for QRT-PCR.
Supplementary Table 1 from Combination Immunotherapy after ASCT for Multiple Myeloma Using MAGE-A3/Poly-ICLC Immunizations Followed by Adoptive Transfer of Vaccine-Primed and Costimulated Autologous T Cells
Authors: Rapoport Aaron P. , Aqui Nicole A. , Stadtmauer Edward A. , Vogl Dan T. , Xu Yin Yan , Kalos Michael , Cai Ling , Fang Hong-Bin , Weiss Brendan M. , Badros Ashraf , Yanovich Saul , Akpek Gorgun , Tsao Patricia , Cross Alan , Mann Dean , Philip Sunita , Kerr Naseem , Brennan Andrea , Zheng Zhaohui , Ruehle Kathleen , Milliron Todd , Strome Scott E. , Salazar Andres M. , Levine Bruce L. , June Carl H.
Published: April 2023

PDF file - 54KB, Adverse Events Table.
Supplementary Figure 1 from Combination Immunotherapy after ASCT for Multiple Myeloma Using MAGE-A3/Poly-ICLC Immunizations Followed by Adoptive Transfer of Vaccine-Primed and Costimulated Autologous T Cells
Authors: Rapoport Aaron P. , Aqui Nicole A. , Stadtmauer Edward A. , Vogl Dan T. , Xu Yin Yan , Kalos Michael , Cai Ling , Fang Hong-Bin , Weiss Brendan M. , Badros Ashraf , Yanovich Saul , Akpek Gorgun , Tsao Patricia , Cross Alan , Mann Dean , Philip Sunita , Kerr Naseem , Brennan Andrea , Zheng Zhaohui , Ruehle Kathleen , Milliron Todd , Strome Scott E. , Salazar Andres M. , Levine Bruce L. , June Carl H.
Published: April 2023

PDF file - 198KB, MAGE-A3 Trojan Peptide Vaccine Reactogenicity.
Supplementary Figure 2 from Glioma Grade Is Associated with the Accumulation and Activity of Cells Bearing M2 Monocyte Markers
Authors: Prosniak Michael , Harshyne Larry A. , Andrews David W. , Kenyon Lawrence C. , Bedelbaeva Kamila , Apanasovich Tatiyana V. , Heber-Katz Ellen , Curtis Mark T. , Cotzia Paolo , Hooper D. Craig
Published: April 2023

PDF - 66K, Co-staining of GBM specimens for the astrocyte/glioma cell marker GFAP and IL-10.
Supplementary Table S2 from Expression Defect Size among Unclassified MLH1 Variants Determines Pathogenicity in Lynch Syndrome Diagnosis
Authors: Hinrichsen Inga , Brieger Angela , Trojan Jörg , Zeuzem Stefan , Nilbert Mef , Plotz Guido
Published: April 2023

PDF file - 120 KB, Clinical evaluation of additional MLH1 variants indicated in gray in Figure 4
Supplementary Table 2 from Proteomic Characterization of Breast Cancer Xenografts Identifies Early and Late Bevacizumab-Induced Responses and Predicts Effective Drug Combinations
Authors: Lindholm Evita M. , Krohn Marit , Iadevaia Sergio , Kristian Alexandr , Mills Gordon B. , Mælandsmo Gunhild M. , Engebraaten Olav
Published: April 2023

PDF file - 36K, Supplementary Table 2: Protein regulation after bevacizumab + doxorubicin combination treatment, compared to doxorubicin monotherapy.
Supplementary Table 1 from Proteomic Characterization of Breast Cancer Xenografts Identifies Early and Late Bevacizumab-Induced Responses and Predicts Effective Drug Combinations
Authors: Lindholm Evita M. , Krohn Marit , Iadevaia Sergio , Kristian Alexandr , Mills Gordon B. , Mælandsmo Gunhild M. , Engebraaten Olav
Published: April 2023

PDF file - 36K, Supplementary Table 1: Protein regulation after Bevacizumab monotherapy.
Supplementary Table 3 from PI3K Pathway Activation in High-Grade Ductal Carcinoma In Situ—Implications for Progression to Invasive Breast Carcinoma
Authors: Sakr Rita A. , Weigelt Britta , Chandarlapaty Sarat , Andrade Victor P. , Guerini-Rocco Elena , Giri Dilip , Ng Charlotte K.Y. , Cowell Catherine F. , Rosen Neal , Reis-Filho Jorge S. , King Tari A.
Published: April 2023

PDF file - 58KB, PIK3CA mutations and mutation frequencies in pure high-grade DCIS and high-grade DCIS associated with IBC.
Supplementary Figure 2 from Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2+ Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831
Authors: Dueck Amylou C. , Reinholz Monica M. , Geiger Xochiquetzal J. , Tenner Kathleen , Ballman Karla , Jenkins Robert B. , Riehle Darren , Chen Beiyun , McCullough Ann E. , Davidson Nancy E. , Martino Silvana , Sledge George W. , Kaufman Peter A. , Kutteh Leila A. , Gralow Julie , Harris Lyndsay N. , Ingle James N. , Lingle Wilma L. , Perez Edith A.
Published: April 2023

Supplementary Figure 2 - PDF file 9846K, Patient Flow Diagram for N9831 MYC IHC Analysis
Supplementary Figure 1 from Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2+ Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831
Authors: Dueck Amylou C. , Reinholz Monica M. , Geiger Xochiquetzal J. , Tenner Kathleen , Ballman Karla , Jenkins Robert B. , Riehle Darren , Chen Beiyun , McCullough Ann E. , Davidson Nancy E. , Martino Silvana , Sledge George W. , Kaufman Peter A. , Kutteh Leila A. , Gralow Julie , Harris Lyndsay N. , Ingle James N. , Lingle Wilma L. , Perez Edith A.
Published: April 2023

Supplementary Figure 1 - PDF file 5863K, NCCTG N9831 Trial Incorporating Trastuzumab in Adjuvant Therapy
Supplementary Figure Legend from Plasma MicroRNA Are Disease Response Biomarkers in Classical Hodgkin Lymphoma
Authors: Jones Kimberley , Nourse Jamie P. , Keane Colm , Bhatnagar Atul , Gandhi Maher K.
Published: April 2023

PDF file - 40K
Supplementary Figure S6 from Targeting Small Cell Lung Cancer Harboring PIK3CA Mutation with a Selective Oral PI3K Inhibitor PF-4989216
Authors: Walls Marlena , Baxi Sangita M. , Mehta Pramod P. , Liu Kevin K.-C. , Zhu JinJiang , Estrella Heather , Li Chunze , Zientek Michael , Zong Qing , Smeal Tod , Yin Min-Jean
Published: April 2023

PDF file 117K, Supplementary Figure S6: Profile of BIM isoforms in SCLC lines treated with a variety of cytotoxic agent
Supplementary Figure S4 from Targeting Small Cell Lung Cancer Harboring PIK3CA Mutation with a Selective Oral PI3K Inhibitor PF-4989216
Authors: Walls Marlena , Baxi Sangita M. , Mehta Pramod P. , Liu Kevin K.-C. , Zhu JinJiang , Estrella Heather , Li Chunze , Zientek Michael , Zong Qing , Smeal Tod , Yin Min-Jean
Published: April 2023

PDF file 216K, Supplementary Figure S4: PF-4989216 inhibited anchorage independent growth of SCLCs with PIK3CA mutation
Supplementary Figure S1 from Targeting Small Cell Lung Cancer Harboring PIK3CA Mutation with a Selective Oral PI3K Inhibitor PF-4989216
Authors: Walls Marlena , Baxi Sangita M. , Mehta Pramod P. , Liu Kevin K.-C. , Zhu JinJiang , Estrella Heather , Li Chunze , Zientek Michael , Zong Qing , Smeal Tod , Yin Min-Jean
Published: April 2023

PDF file 52K, Supplementary Figure S1: PIK3CA mutation locations and PF-4989216 characteristics
Supplementary Table 3 from Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)
Authors: Nathanson Katherine L. , Martin Anne-Marie , Wubbenhorst Bradley , Greshock Joel , Letrero Richard , D'Andrea Kurt , O'Day Steven , Infante Jeffrey R. , Falchook Gerald S. , Arkenau Hendrik-Tobias , Millward Michael , Brown Michael P. , Pavlick Anna , Davies Michael A. , Ma Bo , Gagnon Robert , Curtis Martin , Lebowitz Peter F. , Kefford Richard , Long Georgina V.
Published: April 2023

Supplementary Table 3 - PDF file 47K, Gene specific list used for correlation, with aggregate percentages of gains and losses in the archival/pre-treatment samples and PFS analysis
Supplementary Table 4 from BET Bromodomain Inhibition of MYC-Amplified Medulloblastoma
Authors: Bandopadhayay Pratiti , Bergthold Guillaume , Nguyen Brian , Schubert Simone , Gholamin Sharareh , Tang Yujie , Bolin Sara , Schumacher Steven E. , Zeid Rhamy , Masoud Sabran , Yu Furong , Vue Nujsaubnusi , Gibson William J. , Paolella Brenton R. , Mitra Siddhartha S. , Cheshier Samuel H. , Qi Jun , Liu Kun-Wei , Wechsler-Reya Robert , Weiss William A. , Swartling Fredrik J. , Kieran Mark W. , Bradner James E. , Beroukhim Rameen , Cho Yoon-Jae
Published: April 2023

PDF file - 71K, Differentially expressed genes following treatment with JQ1.
Supplementary Figure 2 from Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)
Authors: Nathanson Katherine L. , Martin Anne-Marie , Wubbenhorst Bradley , Greshock Joel , Letrero Richard , D'Andrea Kurt , O'Day Steven , Infante Jeffrey R. , Falchook Gerald S. , Arkenau Hendrik-Tobias , Millward Michael , Brown Michael P. , Pavlick Anna , Davies Michael A. , Ma Bo , Gagnon Robert , Curtis Martin , Lebowitz Peter F. , Kefford Richard , Long Georgina V.
Published: April 2023

Supplementary Figure 2 - PDF file 252K, Copy number in baseline samples comparing patients with V600E vs. V600K mutations
Suppementary Table 4 from Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)
Authors: Nathanson Katherine L. , Martin Anne-Marie , Wubbenhorst Bradley , Greshock Joel , Letrero Richard , D'Andrea Kurt , O'Day Steven , Infante Jeffrey R. , Falchook Gerald S. , Arkenau Hendrik-Tobias , Millward Michael , Brown Michael P. , Pavlick Anna , Davies Michael A. , Ma Bo , Gagnon Robert , Curtis Martin , Lebowitz Peter F. , Kefford Richard , Long Georgina V.
Published: April 2023

Suppementary Table 4 - PDF file 38K, Correlation analysis of selected genes from aCGH data
Supplementary Figure 2 from BET Bromodomain Inhibition of MYC-Amplified Medulloblastoma
Authors: Bandopadhayay Pratiti , Bergthold Guillaume , Nguyen Brian , Schubert Simone , Gholamin Sharareh , Tang Yujie , Bolin Sara , Schumacher Steven E. , Zeid Rhamy , Masoud Sabran , Yu Furong , Vue Nujsaubnusi , Gibson William J. , Paolella Brenton R. , Mitra Siddhartha S. , Cheshier Samuel H. , Qi Jun , Liu Kun-Wei , Wechsler-Reya Robert , Weiss William A. , Swartling Fredrik J. , Kieran Mark W. , Bradner James E. , Beroukhim Rameen , Cho Yoon-Jae
Published: April 2023

PDF file - 386K, A, Cell viability relative to day 0 is shown following the indicated treatments in the indicated cell lines. Error bars represent the mean plus-minus SD of three replicates per condition. B, qPCR assessment of MYC mRNA expression in three MYC-amplified patient derived medulloblastoma cell lines treated with JQ1R or JQ1S at doses shown. Values represent mean plus-minus SD of six replicate measurements.
Supplementary Figure 6 from T Lymphocytes Redirected against the Chondroitin Sulfate Proteoglycan-4 Control the Growth of Multiple Solid Tumors both In Vitro and In Vivo
Authors: Geldres Claudia , Savoldo Barbara , Hoyos Valentina , Caruana Ignazio , Zhang Ming , Yvon Eric , Del Vecchio Michele , Creighton Chad J. , Ittmann Michael , Ferrone Soldano , Dotti Gianpietro
Published: April 2023

PDF file - 125K, Immunohistochemistry, flow cytometry and survival curve analysis of the melanoma xenograft model. Panel A illustrates the expression of CSPG4 in tumor samples (SENMA) isolated 30 days after infusion of either CAR.CSPG4+ T cells or control T cells. Panel B. FACs analysis to detect tumor cells and CD3+ T cells in tumor biopsy, blood and spleen collected from mice at day 30 post tumor (SENMA) injection. Panel C. Survival curve of the melanoma xenograft model. Data are representative of 15 control and treated mice. Log-rank test: p<0.0001.
Supplementary Figure 5 from Stearoyl-CoA Desaturase 1 Is a Novel Molecular Therapeutic Target for Clear Cell Renal Cell Carcinoma
Authors: von Roemeling Christina A. , Marlow Laura A. , Wei Johnny J. , Cooper Simon J. , Caulfield Thomas R. , Wu Kevin , Tan Winston W. , Tun Han W. , Copland John A.
Published: April 2023

Supplementary Figure 5: mono and combo effects of temsirolimus - PDF file 350K, Monotherapeutic Dose out of the mTOR inhibitor temsirolimus in ccRCC cell lines
Supplementary Figure 4 from Stearoyl-CoA Desaturase 1 Is a Novel Molecular Therapeutic Target for Clear Cell Renal Cell Carcinoma
Authors: von Roemeling Christina A. , Marlow Laura A. , Wei Johnny J. , Cooper Simon J. , Caulfield Thomas R. , Wu Kevin , Tan Winston W. , Tun Han W. , Copland John A.
Published: April 2023

Supplementary Figure 4: mono and combo effects of pazopanic and sunitinib - PDF file 1678K, Monotherapeutic dose out of pazopanib and sunitinib, and combinatorial effects with SCD1 inhibitor in ccRCC cells
Supplementary Figure 1 from Stearoyl-CoA Desaturase 1 Is a Novel Molecular Therapeutic Target for Clear Cell Renal Cell Carcinoma
Authors: von Roemeling Christina A. , Marlow Laura A. , Wei Johnny J. , Cooper Simon J. , Caulfield Thomas R. , Wu Kevin , Tan Winston W. , Tun Han W. , Copland John A.
Published: April 2023

Supplementary Figure 1: Validation of RWV-366T - PDF file 5154K, Verification of renal origins and confirmation of patient tissue match for RWV-366T ccRCC cell line
Supplementary Table 1 from MGMT-STP27 Methylation Status as Predictive Marker for Response to PCV in Anaplastic Oligodendrogliomas and Oligoastrocytomas. A Report from EORTC Study 26951
Authors: van den Bent Martin J. , Erdem-Eraslan Lale , Idbaih Ahmed , de Rooi Johan , Eilers Paul H.C. , Spliet Wim G.M. , den Dunnen Wilfred F.A. , Tijssen Cees , Wesseling Pieter , Sillevis Smitt Peter A.E. , Kros Johan M. , Gorlia Thierry , French Pim J.
Published: April 2023

Supplementary Table 1 - PDF file 67K, Clinical and molecular characteristics of patients
Supplementary Figure legends from MGMT-STP27 Methylation Status as Predictive Marker for Response to PCV in Anaplastic Oligodendrogliomas and Oligoastrocytomas. A Report from EORTC Study 26951
Authors: van den Bent Martin J. , Erdem-Eraslan Lale , Idbaih Ahmed , de Rooi Johan , Eilers Paul H.C. , Spliet Wim G.M. , den Dunnen Wilfred F.A. , Tijssen Cees , Wesseling Pieter , Sillevis Smitt Peter A.E. , Kros Johan M. , Gorlia Thierry , French Pim J.
Published: April 2023

Supplementary figure legends - PDF file 23K, Supplementary figure legends
Supplementary Table 2 from Molecular Classification of Malignant Pleural Mesothelioma: Identification of a Poor Prognosis Subgroup Linked to the Epithelial-to-Mesenchymal Transition
Authors: de Reyniès Aurélien , Jaurand Marie-Claude , Renier Annie , Couchy Gabrielle , Hysi Ilir , Elarouci Nabila , Galateau-Sallé Françoise , Copin Marie-Christine , Hofman Paul , Cazes Aurélie , Andujar Pascal , Imbeaud Sandrine , Petel Fabien , Pairon Jean-Claude , Le Pimpec-Barthes Francoise , Zucman-Rossi Jessica , Jean Didier
Published: April 2023

XLS file - 11306KB, Pathway analysis.
Supplementary Figure 1 from Margin-Infiltrating CD20+ B Cells Display an Atypical Memory Phenotype and Correlate with Favorable Prognosis in Hepatocellular Carcinoma
Authors: Shi Jie-Yi , Gao Qiang , Wang Zhi-Chao , Zhou Jian , Wang Xiao-Ying , Min Zhi-Hui , Shi Ying-Hong , Shi Guo-Ming , Ding Zhen-Bin , Ke Ai-Wu , Dai Zhi , Qiu Shuang-Jian , Song Kang , Fan Jia
Published: April 2023

PDF file - 569K, The expressions of HLA-ABC and HLA-DR in L-02 (a normal human liver cell line), HepG2 (a low-metastatic human HCC cell line) and 97H.
Supplementary Figure 2 from JMJD2B Promotes Epithelial–Mesenchymal Transition by Cooperating with β-Catenin and Enhances Gastric Cancer Metastasis
Authors: Zhao Li , Li Wenjuan , Zang Wen , Liu Zhifang , Xu Xia , Yu Han , Yang Qing , Jia Jihui
Published: April 2023

PDF file - 282K, Supplementary Figure S2 JMJD2B stimulates TCF/Beta-catenin-dependent transcription.
Supplementary Table 5 from Identification of Lethal microRNAs Specific for Head and Neck Cancer
Authors: Lindenbergh-van der Plas Marlon , Martens-de Kemp Sanne R. , de Maaker Michiel , van Wieringen Wessel N. , Ylstra Bauke , Agami Reuven , Cerisoli Francesco , Leemans C. René , Braakhuis Boudewijn J.M. , Brakenhoff Ruud H.
Published: April 2023

PDF file, 153K, Predicted binding sites of the six tumor-selective microRNAs in ATM and CD40.
Supplementary Figure 1 from Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer
Authors: Cardnell Robert J. , Feng Ying , Diao Lixia , Fan You-Hong , Masrorpour Fatemah , Wang Jing , Shen Yuqiao , Mills Gordon B. , Minna John D. , Heymach John V. , Byers Lauren A.
Published: April 2023

PDF file - 233K, Plots correlating protein expression for components of the DNA Repair Score not shown in Figure 3.
Supplementary Figure Text from T-cell Responses to Oncogenic Merkel Cell Polyomavirus Proteins Distinguish Patients with Merkel Cell Carcinoma from Healthy Donors
Authors: Lyngaa Rikke , Pedersen Natasja Wulff , Schrama David , Thrue Charlotte Albæk , Ibrani Dafina , Met Özcan , thor Straten Per , Nghiem Paul , Becker Jürgen C. , Hadrup Sine Reker
Published: April 2023

PDF file 100K, Supplementary figure legend
Supplementary Figure S4 from T-cell Responses to Oncogenic Merkel Cell Polyomavirus Proteins Distinguish Patients with Merkel Cell Carcinoma from Healthy Donors
Authors: Lyngaa Rikke , Pedersen Natasja Wulff , Schrama David , Thrue Charlotte Albæk , Ibrani Dafina , Met Özcan , thor Straten Per , Nghiem Paul , Becker Jürgen C. , Hadrup Sine Reker
Published: April 2023

PDF file 94K, Expression of HLA class 1 and LTA
Supplementary Figure 5 from An Unconventional KITENIN/ErbB4-Mediated Downstream Signal of EGF Upregulates c-Jun and the Invasiveness of Colorectal Cancer Cells
Authors: Bae Jeong A. , Yoon Somy , Park So-Yeon , Lee Jae Hyuk , Hwang Jun-Eul , Kim Hangun , Seo Young-Woo , Cha Yoon Jin , Hong Sung Pil , Kim Hoguen , Chung Ik Joo , Kim Kyung Keun
Published: April 2023

PDF file - 143K, Figure 5. Dvl2-knockdown does not increase transcription of c-Jun and Dvl2 does not interact with c-Jun.
Supplementary Figure 4 from An Unconventional KITENIN/ErbB4-Mediated Downstream Signal of EGF Upregulates c-Jun and the Invasiveness of Colorectal Cancer Cells
Authors: Bae Jeong A. , Yoon Somy , Park So-Yeon , Lee Jae Hyuk , Hwang Jun-Eul , Kim Hangun , Seo Young-Woo , Cha Yoon Jin , Hong Sung Pil , Kim Hoguen , Chung Ik Joo , Kim Kyung Keun
Published: April 2023

PDF file - 158K, Figure 4. Effects of Dvl2-knockdown on c-Jun and of EGF on c-Jun/Dvl2 level in KITENIN-transfected cells.
Supplementary Figure 2 from An Unconventional KITENIN/ErbB4-Mediated Downstream Signal of EGF Upregulates c-Jun and the Invasiveness of Colorectal Cancer Cells
Authors: Bae Jeong A. , Yoon Somy , Park So-Yeon , Lee Jae Hyuk , Hwang Jun-Eul , Kim Hangun , Seo Young-Woo , Cha Yoon Jin , Hong Sung Pil , Kim Hoguen , Chung Ik Joo , Kim Kyung Keun
Published: April 2023

PDF file - 177K, Figure 2. Effects of functional blockade of EGFR via treatment of an anti-EGFR monoclonal antibody on enhanced cell invasion by EGF.
Supplementary Methods from C-Reactive Protein Downregulates TRAIL Expression in Human Peripheral Monocytes via an Egr-1–Dependent Pathway
Authors: Secchiero Paola , Rimondi Erika , di Iasio Maria Grazia , Agnoletto Chiara , Melloni Elisabetta , Volpi Ilaria , Zauli Giorgio
Published: April 2023

PDF file - 98K
Supplementary Figure 3 from Deciphering the Mechanisms of Tumorigenesis in Human Pancreatic Ductal Epithelial Cells
Authors: Chang Zhe , Li Zhongkui , Wang Xiaoyang , Kang Ya'an , Yuan Yuhui , Niu Jiangong , Wang Huamin , Chatterjee Deyali , Fleming Jason B. , Li Min , Abbruzzese James L. , Chiao Paul J.
Published: April 2023

PDF file - 96K, Supplementary Fig. 3. Confirmation of gene expression change of BMP7 and GRB10 in cDNA microarray analysis.
Supplementary Figure 8 from Notch Pathway Activity Identifies Cells with Cancer Stem Cell–like Properties and Correlates with Worse Survival in Lung Adenocarcinoma
Authors: Hassan Khaled A. , Wang Luo , Korkaya Hasan , Chen Guoan , Maillard Ivan , Beer David G. , Kalemkerian Gregory P. , Wicha Max S.
Published: April 2023

PDF file - 89K, Relative gene expression of cancer stem cell related genes based on Notch activity.
Supplementary Figure 6 from Notch Pathway Activity Identifies Cells with Cancer Stem Cell–like Properties and Correlates with Worse Survival in Lung Adenocarcinoma
Authors: Hassan Khaled A. , Wang Luo , Korkaya Hasan , Chen Guoan , Maillard Ivan , Beer David G. , Kalemkerian Gregory P. , Wicha Max S.
Published: April 2023

PDF file - 467K, Representative immunohistochemical staining for Hes-1 protein, in primary NSCLC tissue micro array and NCI-H1299 xenograft.
Supplementary Figure 4 from Notch Pathway Activity Identifies Cells with Cancer Stem Cell–like Properties and Correlates with Worse Survival in Lung Adenocarcinoma
Authors: Hassan Khaled A. , Wang Luo , Korkaya Hasan , Chen Guoan , Maillard Ivan , Beer David G. , Kalemkerian Gregory P. , Wicha Max S.
Published: April 2023

PDF file - 184K, Supporting data for Notch reporter specificity, Notch activity and MRK003 specific targeting of Notch pathway.
Supplementary Figure 3 from Notch Pathway Activity Identifies Cells with Cancer Stem Cell–like Properties and Correlates with Worse Survival in Lung Adenocarcinoma
Authors: Hassan Khaled A. , Wang Luo , Korkaya Hasan , Chen Guoan , Maillard Ivan , Beer David G. , Kalemkerian Gregory P. , Wicha Max S.
Published: April 2023

PDF file - 82K, Relative expression of Notch receptors and ligands in multiple NSCLC cell lines transduced with Notch reporter.
Supplementary Figure Legend from Mechanisms of Activity of the TORC1 Inhibitor Everolimus in Waldenstrom Macroglobulinemia
Authors: Roccaro Aldo M. , Sacco Antonio , Jia Xiaojing , Banwait Ranjit , Maiso Patricia , Azab Feda , Flores Ludmila , Manier Salomon , Azab Abdel Kareem , Ghobrial Irene M.
Published: April 2023

PDF file - 38K
Supplementary Tables 1-3 from Early Telomere Shortening and Genomic Instability in Tubo-Ovarian Preneoplastic Lesions
Authors: Chene Gautier , Tchirkov Andrei , Pierre-Eymard Eleonore , Dauplat Jacques , Raoelfils Ines , Cayre Anne , Watkin Emmanuel , Vago Philippe , Penault-Llorca Frederique
Published: April 2023

Supplementary Tables 1-3 - PDF file 74K, aCGH data; minimal regions of interest in tubo-ovarian dysplasia and in STIC; Table S1 : Minimal regions of interest in ovarian dyaplasia (n=5); Table S2 : Minimal regions of interest in the common losses and gains in tubal dysplasia (n=9) 2; Table S3 : Minimal regions of interest in the common losses and gains in STIC (n=12)
Supplementary Table 1 from A Phase I Trial of Dasatinib, an Src-Family Kinase Inhibitor, in Combination with Paclitaxel and Carboplatin in Patients with Advanced or Recurrent Ovarian Cancer
Authors: Secord Angeles Alvarez , Teoh Deanna K. , Barry William T. , Yu Miao , Broadwater Gloria , Havrilesky Laura J. , Lee Paula S. , Berchuck Andrew , Lancaster Johnathan , Wenham Robert M.
Published: April 2023

PDF file, 73K, Extended Toxicity Information.
Supplementary Table 1 from First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors
Authors: Martinez-Garcia Maria , Banerji Udai , Albanell Joan , Bahleda Rastilav , Dolly Saoirse , Kraeber-Bodéré Françoise , Rojo Federico , Routier Emilie , Guarin Ernesto , Xu Zhi-Xin , Rueger Ruediger , Tessier Jean J. L. , Shochat Eliezer , Blotner Steve , Naegelen Valerie Meresse , Soria Jean-Charles
Published: April 2023

PDF file, 9K, Summary of pharmacokinetics of RO4987655 in patients following oral administration.
Supplementary Methods from Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical Models
Authors: Spoerke Jill M. , O'Brien Carol , Huw Ling , Koeppen Hartmut , Fridlyand Jane , Brachmann Rainer K. , Haverty Peter M. , Pandita Ajay , Mohan Sankar , Sampath Deepak , Friedman Lori S. , Ross Leanne , Hampton Garret M. , Amler Lukas C. , Shames David S. , Lackner Mark R.
Published: April 2023

PDF file - 110K
Supplementary Tables 1 - 5 from Pre-Invasive Ovarian Mucinous Tumors Are Characterized by CDKN2A and RAS Pathway Aberrations
Authors: Hunter Sally M. , Gorringe Kylie L. , Christie Michael , Rowley Simone M. , Bowtell David D. , Campbell Ian G.
Published: April 2023

PDF file, 747K, Supplementary data: sequencing primers, integration of CDKN2A/2B copy number events with oncogenic mutations, tissue microarray IHC scoring, representative images of IHC staining, copy number segmentation.
Supplementary Table S1 from A Phase I, Open-Label Study of Siltuximab, an Anti–IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease
Authors: Kurzrock Razelle , Voorhees Peter M. , Casper Corey , Furman Richard R. , Fayad Luis , Lonial Sagar , Borghaei Hossein , Jagannath Sundar , Sokol Lubomir , Usmani Saad Z. , van de Velde Helgi , Qin Xiang , Puchalski Thomas A. , Hall Brett , Reddy Manjula , Qi Ming , van Rhee Frits
Published: April 2023

Supplementary Table S1 - PDF file Percent change from baseline in serum C-reactive protein concentration (mg/L) in Cohort 7
Figure S2 from A Phase I, Open-Label Study of Siltuximab, an Anti–IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease
Authors: Kurzrock Razelle , Voorhees Peter M. , Casper Corey , Furman Richard R. , Fayad Luis , Lonial Sagar , Borghaei Hossein , Jagannath Sundar , Sokol Lubomir , Usmani Saad Z. , van de Velde Helgi , Qin Xiang , Puchalski Thomas A. , Hall Brett , Reddy Manjula , Qi Ming , van Rhee Frits
Published: April 2023

Figure S2 - PDF 22K, C-reactive protein (CRP) and gamma M-spike levels in a patient with light-chain multiple myeloma who received siltuximab 12 mg/kg q3w and had confirmed complete response lasting >12 months
Supplementary Figure 4 from Small-Molecule RA-9 Inhibits Proteasome-Associated DUBs and Ovarian Cancer In Vitro and In Vivo via Exacerbating Unfolded Protein Responses
Authors: Coughlin Kathleen , Anchoori Ravi , Iizuka Yoshie , Meints Joyce , MacNeill Lauren , Vogel Rachel Isaksson , Orlowski Robert Z. , Lee Michael K. , Roden Richard B.S. , Bazzaro Martina
Published: April 2023

PDF file - 272KB, Effect of RA-9 treatment on GCN2 expression levels.
Supplementary Figure 4 from Enhancement of Human Cancer Cell Motility and Invasiveness by Anaphylatoxin C5a via Aberrantly Expressed C5a Receptor (CD88)
Authors: Nitta Hidetoshi , Wada Yoshihiro , Kawano Yoshiaki , Murakami Yoji , Irie Atsushi , Taniguchi Keisuke , Kikuchi Ken , Yamada Gen , Suzuki Kentaro , Honda Jiro , Wilson-Morifuji Masayo , Araki Norie , Eto Masatoshi , Baba Hideo , Imamura Takahisa
Published: April 2023

PDF file - 503K, Detection of C5a in human plasma incubated with cancer cells
Supplementary Figure 2, Video 4 from Enhancement of Human Cancer Cell Motility and Invasiveness by Anaphylatoxin C5a via Aberrantly Expressed C5a Receptor (CD88)
Authors: Nitta Hidetoshi , Wada Yoshihiro , Kawano Yoshiaki , Murakami Yoji , Irie Atsushi , Taniguchi Keisuke , Kikuchi Ken , Yamada Gen , Suzuki Kentaro , Honda Jiro , Wilson-Morifuji Masayo , Araki Norie , Eto Masatoshi , Baba Hideo , Imamura Takahisa
Published: April 2023

AVI file - 16396K, Time-lapse video analysis-C5aR(+)C5a(+)
Supplementary Figure 2, Video 3 from Enhancement of Human Cancer Cell Motility and Invasiveness by Anaphylatoxin C5a via Aberrantly Expressed C5a Receptor (CD88)
Authors: Nitta Hidetoshi , Wada Yoshihiro , Kawano Yoshiaki , Murakami Yoji , Irie Atsushi , Taniguchi Keisuke , Kikuchi Ken , Yamada Gen , Suzuki Kentaro , Honda Jiro , Wilson-Morifuji Masayo , Araki Norie , Eto Masatoshi , Baba Hideo , Imamura Takahisa
Published: April 2023

AVI file - 15325K, Time-lapse video analysis-C5aR(+)C5a(-)
Supplementary Methods, Figures 1 - 7, and Tables 1 - 6 from Radiation-Enhanced Lung Cancer Progression in a Transgenic Mouse Model of Lung Cancer Is Predictive of Outcomes in Human Lung and Breast Cancer
Authors: Delgado Oliver , Batten Kimberly G. , Richardson James A. , Xie Xian-Jin , Gazdar Adi F. , Kaisani Aadil A. , Girard Luc , Behrens Carmen , Suraokar Milind , Fasciani Gail , Wright Woodring E. , Story Michael D. , Wistuba Ignacio I. , Minna John D. , Shay Jerry W.
Published: April 2023

PDF file - 1617KB, Figure S1. Malignant Characteristics of Invasive Adenocarcinoma in K-rasLA1 Mice; Figure S2. Radiation Effects on the Incidence of Various Endpoints in K-rasLA1 Mice; Figure S3. Comparative Genomic Analyses and Classifier Isolation from Irradiated Versus Unirradiated Control K-rasLA1 Mice; Figure S4. Comparative Genomic Analysis of Whole Lungs Reveals Unique Gene Classifiers Capable of Specifying Individual Experimental Cohorts; Figure S5. Only "Fractionated" Classifier Demonstrates Clinical Relevance for Lung Cancer Patient Survival; Figure S6. "Fractionated" Classifier Capable of Predicting Overall Survival in Patients with Breast, but not Lung Squamous Cell Cancer; Supplementary Figure S7. Cox Regression Analysis Exposes 6 Genes Within "Fractionated" Classifier Which Retain Predictive Capacity; Table S1. Logistic Regression Analysis of Unirradiated K-rasLA1 Mice for Gender and Strain Effects on Various Endpoints; Table S2. Logistic Regression Analysis for Gender and Strain Effects on Various Endpoints Controlling for Experiment; Table S3. Logistic Regression Analysis of Radiation Effects on the Incidence of Invasive Adenocarcinoma Controlling for Gender and Strain; Table S4. Multivariate Cox Analysis for Gender and Strain Effects on Overall Survival Controlling for Experiment; Table S5. Multivariate Cox Analysis of Radiation Effects on Overall Survival Controlling for Gender and Strain Effects; Table S6. IPA Network Annotations Associated with Corresponding Gene Lists.
Supplementary Figure 2 from Enhancement of Human Cancer Cell Motility and Invasiveness by Anaphylatoxin C5a via Aberrantly Expressed C5a Receptor (CD88)
Authors: Nitta Hidetoshi , Wada Yoshihiro , Kawano Yoshiaki , Murakami Yoji , Irie Atsushi , Taniguchi Keisuke , Kikuchi Ken , Yamada Gen , Suzuki Kentaro , Honda Jiro , Wilson-Morifuji Masayo , Araki Norie , Eto Masatoshi , Baba Hideo , Imamura Takahisa
Published: April 2023

PDF file - 407K
Supplementary Figure 3 from Copy Number Aberrations of Genes Regulating Normal Thymus Development in Thymic Epithelial Tumors
Authors: Petrini Iacopo , Wang Yisong , Zucali Paolo A. , Lee Hye Seung , Pham Trung , Voeller Donna , Meltzer Paul S. , Giaccone Giuseppe
Published: April 2023

PDF file - 2727K, Frequency of FOXC1 copy number loss and PBX1 copy number gain in the WHO histotypes overall in the 2 cohorts.
Supplementary Figure 1 from Enhancement of Human Cancer Cell Motility and Invasiveness by Anaphylatoxin C5a via Aberrantly Expressed C5a Receptor (CD88)
Authors: Nitta Hidetoshi , Wada Yoshihiro , Kawano Yoshiaki , Murakami Yoji , Irie Atsushi , Taniguchi Keisuke , Kikuchi Ken , Yamada Gen , Suzuki Kentaro , Honda Jiro , Wilson-Morifuji Masayo , Araki Norie , Eto Masatoshi , Baba Hideo , Imamura Takahisa
Published: April 2023

PDF file - 291K, Expression of C5aR on human primary cancers (A) and non-cancerous cells (B)
Supplementary Figure 1 from Copy Number Aberrations of Genes Regulating Normal Thymus Development in Thymic Epithelial Tumors
Authors: Petrini Iacopo , Wang Yisong , Zucali Paolo A. , Lee Hye Seung , Pham Trung , Voeller Donna , Meltzer Paul S. , Giaccone Giuseppe
Published: April 2023

PDF file - 3704K, Copy number aberrations of genes regulating normal thymus development in the confirmation cohort.